{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:21:31Z","timestamp":1770067291562,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.thromres.2008.02.017","type":"journal-article","created":{"date-parts":[[2008,5,16]],"date-time":"2008-05-16T12:36:20Z","timestamp":1210941380000},"page":"488-497","source":"Crossref","is-referenced-by-count":66,"title":["Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran"],"prefix":"10.1016","volume":"123","author":[{"given":"G.","family":"Agnelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.I.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.T.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bergqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.E.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.R.","family":"Lassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mouret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Rosencher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bylock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Boberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2008.02.017_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","article-title":"The direct thrombin inhibitor melagatran and its oral prodrug H 376\/95: intestinal absorption properties, biochemical and pharmacodynamic effects","volume":"101","author":"Gustafsson","year":"2001","journal-title":"Thromb Res"},{"issue":"Suppl 1","key":"10.1016\/j.thromres.2008.02.017_bib2","article-title":"Single and repeated oral dosing of H 376\/95, a prodrug to the direct thrombin inhibitor melagatran, to young healthy male subjects","volume":"94","author":"Eriksson","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2008.02.017_bib3","article-title":"A comparison of the pharmacokinetics of ximelagatran (pINN, formerly H 376\/95) in young and elderly heALAThy subjects","author":"Johansson","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2008.02.017_bib4","article-title":"The pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376\/95), in orthopaedic surgery patients treated to prevent deep vein thrombosis and pulmonary embolism","author":"Eriksson","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2008.02.017_bib5","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0140-6736(02)11469-3","article-title":"Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial","volume":"360","author":"Eriksson","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2008.02.017_bib6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1055\/s-0037-1613445","article-title":"Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement","volume":"89","author":"Eriksson","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2008.02.017_bib7","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1111\/j.1538-7836.2003.00494.x","article-title":"The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study","volume":"12","author":"Eriksson","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2008.02.017_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2008.02.017_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2008.02.017_bib10","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Olsson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2008.02.017_bib11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2008.02.017_bib12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00002018-200528040-00006","article-title":"Hepatic findings in long-term clinical trials of ximelagatran","volume":"28","author":"Lee","year":"2005","journal-title":"Drug Safety"},{"key":"10.1016\/j.thromres.2008.02.017_bib13","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1161\/CIRCULATIONAHA.105.603100","article-title":"Anticoagulants and transaminase elevation","volume":"113","author":"Arora","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2008.02.017_bib14","series-title":"The European Agency for the Evaluation of Medicinal Products. London","article-title":"Points to consider on clinical investigation of medicinal products for prophylaxis of intra-and postoperative venous thromboembolic risk","year":"2000"},{"key":"10.1016\/j.thromres.2008.02.017_bib15","article-title":"Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis","author":"Kindmark","year":"2007","journal-title":"Pharmacogenomics J."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384808000960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384808000960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T08:41:24Z","timestamp":1557564084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384808000960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0049384808000960"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2008.02.017","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}